Symbols / PVLA Stock $123.59 -2.72% Palvella Therapeutics, Inc.
PVLA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Ratings
Current target
$123.59
Low
$205.00
High
$270.00
Mean
$230.07
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-31 | main | Chardan Capital | Buy → Buy | $240 |
| 2026-03-24 | main | HC Wainwright & Co. | Buy → Buy | $270 |
| 2026-03-16 | main | Chardan Capital | Buy → Buy | $210 |
| 2026-02-25 | main | Mizuho | Outperform → Outperform | $250 |
| 2026-02-25 | main | BTIG | Buy → Buy | $215 |
| 2026-02-24 | main | Chardan Capital | Buy → Buy | $210 |
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $255 |
| 2026-01-29 | reit | BTIG | Buy → Buy | $192 |
| 2026-01-16 | reit | BTIG | Buy → Buy | $192 |
| 2026-01-07 | init | Mizuho | — → Outperform | $205 |
| 2025-12-16 | main | Truist Securities | Buy → Buy | $190 |
| 2025-12-16 | main | Canaccord Genuity | Buy → Buy | $204 |
| 2025-12-16 | main | TD Cowen | Buy → Buy | $133 |
| 2025-12-16 | main | Chardan Capital | Buy → Buy | $174 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $200 |
| 2025-12-15 | main | BTIG | Buy → Buy | $192 |
| 2025-12-05 | init | Clear Street | — → Buy | $200 |
| 2025-12-05 | init | BTIG | — → Buy | $167 |
| 2025-12-04 | init | Craig-Hallum | — → Buy | $175 |
| 2025-11-24 | main | Stifel | Buy → Buy | $145 |
- PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill Fri, 24 Apr 2026 07
- Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN Mon, 27 Apr 2026 03
- Is It Too Late To Consider Palvella Therapeutics (PVLA) After Its 386.8% One Year Surge? - simplywall.st Sun, 26 Apr 2026 01
- Certain Common Stock of Palvella Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com Mon, 27 Apr 2026 00
- New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance Sun, 26 Apr 2026 00
- Palvella (PVLA) Stock Pre-Market (+13%): Phase 3 Topline Data Anticipation - Trefis ue, 24 Feb 2026 08
- PALVELLA THERAPEUTICS ($PVLA) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative ue, 31 Mar 2026 07
- PVLA (Palvella Therapeutics Inc.) posts wider than expected Q4 2025 loss, shares dip 0.69% in today’s trading. - Attention Driven Stocks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 01
- A rare disease drug wins 2 late-breaking spots at a global congress - Stock Titan Mon, 20 Apr 2026 11
- PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits ue, 24 Feb 2026 08
- $PVLA stock is up 37% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 08
- Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance Mon, 12 Jan 2026 08
- Palvella lines up 3 rare-disease trials after $230M financing - Stock Titan ue, 31 Mar 2026 07
- $PVLA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative ue, 31 Mar 2026 07
- Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance Mon, 02 Mar 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
38.60
+173.87%
|
14.10
+18.75%
|
11.87
-34.21%
|
18.04
|
| Research And Development |
|
22.84
+180.22%
|
8.15
-7.30%
|
8.79
-36.67%
|
13.88
|
| Selling General And Administration |
|
15.76
+165.16%
|
5.94
+93.24%
|
3.08
-25.99%
|
4.16
|
| General And Administrative Expense |
|
15.76
+165.16%
|
5.94
+93.24%
|
3.08
-25.99%
|
4.16
|
| Other Gand A |
|
15.76
+165.16%
|
5.94
+93.24%
|
3.08
-25.99%
|
4.16
|
| Total Expenses |
|
38.60
+173.87%
|
14.10
+18.75%
|
11.87
-34.21%
|
18.04
|
| Operating Income |
|
-38.60
-173.87%
|
-14.10
-18.75%
|
-11.87
+34.21%
|
-18.04
|
| Total Operating Income As Reported |
|
-38.60
-173.87%
|
-14.10
-18.75%
|
-11.87
+34.21%
|
-18.04
|
| EBITDA |
|
-35.90
-173.67%
|
-13.12
-170.18%
|
18.69
+203.61%
|
-18.04
|
| Normalized EBITDA |
|
-35.28
-235.86%
|
-10.51
-114.76%
|
-4.89
+72.42%
|
-17.74
|
| EBIT |
|
-35.90
-173.67%
|
-13.12
-170.18%
|
18.69
+203.61%
|
-18.04
|
| Total Unusual Items |
|
-0.61
+76.56%
|
-2.61
-111.07%
|
23.58
+7961.00%
|
-0.30
|
| Total Unusual Items Excluding Goodwill |
|
-0.61
+76.56%
|
-2.61
-111.07%
|
23.58
+7961.00%
|
-0.30
|
| Special Income Charges |
|
—
|
0.00
-100.00%
|
23.10
|
0.00
|
| Other Special Charges |
|
—
|
—
|
-23.10
|
—
|
| Net Income |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Pretax Income |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+165.40%
|
-28.58
|
| Net Non Operating Interest Income Expense |
|
-3.23
+12.16%
|
-3.67
-158.66%
|
6.26
+160.45%
|
-10.36
|
| Interest Expense Non Operating |
|
5.82
+34.77%
|
4.32
|
0.00
|
—
|
| Net Interest Income |
|
-3.23
+12.16%
|
-3.67
-158.66%
|
6.26
+160.45%
|
-10.36
|
| Interest Expense |
|
5.82
+34.77%
|
4.32
|
0.00
|
—
|
| Interest Income Non Operating |
|
2.59
+303.43%
|
0.64
-89.75%
|
6.26
|
—
|
| Interest Income |
|
2.59
+303.43%
|
0.64
-89.75%
|
6.26
|
—
|
| Other Income Expense |
|
0.12
-65.77%
|
0.34
-98.62%
|
24.30
+14062.64%
|
-0.17
|
| Other Non Operating Income Expenses |
|
0.73
-75.33%
|
2.95
+313.90%
|
0.71
+465.08%
|
0.13
|
| Gain On Sale Of Security |
|
-0.61
+76.56%
|
-2.61
-638.35%
|
0.48
+261.67%
|
-0.30
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
+100.00%
|
-1.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
+100.00%
|
-0.01
|
| Net Income Including Noncontrolling Interests |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Net Income From Continuing Operation Net Minority Interest |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Net Income From Continuing And Discontinued Operation |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Net Income Continuous Operations |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Normalized Income |
|
-41.10
-177.29%
|
-14.82
-203.00%
|
-4.89
+82.06%
|
-27.26
|
| Net Income Common Stockholders |
|
-41.72
-139.27%
|
-17.43
-197.32%
|
17.91
+165.02%
|
-27.55
|
| Diluted EPS |
|
-3.71
+52.62%
|
-7.83
-590.44%
|
1.60
+165.02%
|
-2.46
|
| Basic EPS |
|
-3.71
+52.62%
|
-7.83
-590.44%
|
1.60
+165.02%
|
-2.46
|
| Basic Average Shares |
|
11.25
+405.46%
|
2.23
-80.16%
|
11.22
+0.00%
|
11.22
|
| Diluted Average Shares |
|
11.25
+405.46%
|
2.23
-80.16%
|
11.22
+0.00%
|
11.22
|
| Diluted NI Availto Com Stockholders |
|
-41.72
-139.27%
|
-17.43
-197.32%
|
17.91
+165.02%
|
-27.55
|
| Preferred Stock Dividends |
|
—
|
—
|
0.78
|
—
|
| Total Other Finance Cost |
|
—
|
—
|
-6.26
-160.45%
|
10.36
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
59.56
-32.50%
|
88.23
+1068.97%
|
7.55
-54.32%
|
16.52
|
| Current Assets |
|
58.99
-33.15%
|
88.23
+1068.97%
|
7.55
-54.32%
|
16.52
|
| Cash Cash Equivalents And Short Term Investments |
|
57.98
-30.65%
|
83.60
+1037.44%
|
7.35
-54.21%
|
16.05
|
| Cash And Cash Equivalents |
|
57.98
-30.65%
|
83.60
+1037.44%
|
7.35
-54.21%
|
16.05
|
| Receivables |
|
0.00
-100.00%
|
2.34
|
0.00
|
—
|
| Accounts Receivable |
|
0.00
-100.00%
|
0.36
|
0.00
|
—
|
| Taxes Receivable |
|
0.00
-100.00%
|
1.98
|
0.00
|
—
|
| Other Current Assets |
|
1.00
-56.23%
|
2.30
+1059.60%
|
0.20
-57.96%
|
0.47
|
| Total Non Current Assets |
|
0.57
|
0.00
|
0.00
|
0.00
|
| Net PPE |
|
0.57
|
0.00
|
—
|
—
|
| Gross PPE |
|
0.57
|
0.00
|
—
|
—
|
| Properties |
|
0.00
|
0.00
|
—
|
—
|
| Buildings And Improvements |
|
0.57
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
31.58
+23.21%
|
25.63
+124.25%
|
11.43
-71.21%
|
39.70
|
| Current Liabilities |
|
11.34
-5.77%
|
12.04
+410.08%
|
2.36
-59.18%
|
5.78
|
| Payables And Accrued Expenses |
|
6.33
+9.11%
|
5.80
+187.60%
|
2.02
-58.53%
|
4.86
|
| Payables |
|
4.59
+0.20%
|
4.59
+389.96%
|
0.94
-70.58%
|
3.18
|
| Accounts Payable |
|
4.59
+0.20%
|
4.59
+389.96%
|
0.94
-70.58%
|
3.18
|
| Current Accrued Expenses |
|
1.73
+42.82%
|
1.21
+12.22%
|
1.08
-35.71%
|
1.68
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.92
-37.68%
|
3.07
+1656.00%
|
0.17
-77.03%
|
0.76
|
| Current Debt And Capital Lease Obligation |
|
0.20
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.20
|
0.00
|
—
|
—
|
| Other Current Liabilities |
|
2.90
-8.40%
|
3.17
+1773.96%
|
0.17
+6.29%
|
0.16
|
| Total Non Current Liabilities Net Minority Interest |
|
20.23
+48.89%
|
13.59
+49.86%
|
9.07
-73.26%
|
33.92
|
| Long Term Debt And Capital Lease Obligation |
|
0.43
|
0.00
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
0.43
|
0.00
|
—
|
—
|
| Other Non Current Liabilities |
|
17.76
+48.72%
|
11.94
+48.27%
|
8.05
-75.16%
|
32.42
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
70.60
+0.00%
|
70.60
|
| Stockholders Equity |
|
27.98
-55.30%
|
62.61
+1713.58%
|
-3.88
+83.26%
|
-23.17
|
| Common Stock Equity |
|
27.98
-55.30%
|
62.61
+184.06%
|
-74.48
+20.57%
|
-93.78
|
| Capital Stock |
|
0.01
+9.09%
|
0.01
-99.98%
|
70.60
+0.00%
|
70.60
|
| Common Stock |
|
0.01
+9.09%
|
0.01
|
0.00
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
-100.00%
|
70.60
+0.00%
|
70.60
|
| Share Issued |
|
12.38
+12.43%
|
11.01
+0.00%
|
11.01
-1.86%
|
11.22
|
| Ordinary Shares Number |
|
12.38
+12.43%
|
11.01
+0.00%
|
11.01
-1.86%
|
11.22
|
| Additional Paid In Capital |
|
163.34
+4.48%
|
156.33
+8498.90%
|
1.82
+49.63%
|
1.22
|
| Retained Earnings |
|
-135.45
-44.50%
|
-93.73
-22.85%
|
-76.30
+19.68%
|
-94.99
|
| Gains Losses Not Affecting Retained Earnings |
|
0.08
+2666.67%
|
0.00
|
0.00
|
—
|
| Other Equity Adjustments |
|
0.08
+2666.67%
|
0.00
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
27.98
-55.30%
|
62.61
+1713.58%
|
-3.88
+83.26%
|
-23.17
|
| Total Capitalization |
|
27.98
-55.30%
|
62.61
+1713.58%
|
-3.88
+83.26%
|
-23.17
|
| Working Capital |
|
47.64
-37.47%
|
76.20
+1368.70%
|
5.19
-51.70%
|
10.74
|
| Invested Capital |
|
27.98
-55.30%
|
62.61
+184.06%
|
-74.48
+20.57%
|
-93.78
|
| Total Debt |
|
0.63
|
0.00
|
—
|
—
|
| Capital Lease Obligations |
|
0.63
|
0.00
|
—
|
—
|
| Net Tangible Assets |
|
27.98
-55.30%
|
62.61
+1713.58%
|
-3.88
+83.26%
|
-23.17
|
| Tangible Book Value |
|
27.98
-55.30%
|
62.61
+184.06%
|
-74.48
+20.57%
|
-93.78
|
| Derivative Product Liabilities |
|
2.04
+23.92%
|
1.65
+62.43%
|
1.01
-32.35%
|
1.50
|
| Preferred Stock Equity |
|
—
|
—
|
70.60
+0.00%
|
70.60
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-25.01
-130.68%
|
-10.84
+20.89%
|
-13.70
+7.66%
|
-14.84
|
| Cash Flow From Continuing Operating Activities |
|
-25.01
-130.68%
|
-10.84
+20.89%
|
-13.70
+7.66%
|
-14.84
|
| Net Income From Continuing Operations |
|
-41.72
-139.27%
|
-17.43
-193.27%
|
18.69
+167.84%
|
-27.55
|
| Other Non Cash Items |
|
5.88
+75.73%
|
3.35
+111.40%
|
-29.36
-383.32%
|
10.36
|
| Stock Based Compensation |
|
6.40
+671.20%
|
0.83
+37.65%
|
0.60
+41.22%
|
0.43
|
| Operating Gains Losses |
|
0.61
-76.56%
|
2.61
+638.35%
|
-0.48
-261.67%
|
0.30
|
| Gain Loss On Investment Securities |
|
0.61
-76.56%
|
2.61
+638.35%
|
-0.48
-261.67%
|
0.30
|
| Change In Working Capital |
|
3.82
+2077.20%
|
-0.19
+93.87%
|
-3.15
-294.26%
|
1.62
|
| Change In Receivables |
|
2.49
+225.99%
|
-1.98
|
0.00
|
—
|
| Changes In Account Receivables |
|
0.39
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
1.36
+190.75%
|
-1.50
-650.55%
|
0.27
-60.72%
|
0.69
|
| Change In Payables And Accrued Expense |
|
-0.04
-101.22%
|
3.29
+196.08%
|
-3.42
-469.55%
|
0.93
|
| Change In Accrued Expense |
|
-1.30
-223.81%
|
1.05
+189.21%
|
-1.18
-11.67%
|
-1.05
|
| Change In Payable |
|
1.26
-43.70%
|
2.24
+199.69%
|
-2.25
-213.38%
|
1.98
|
| Change In Account Payable |
|
1.26
-43.70%
|
2.24
+199.69%
|
-2.25
-213.38%
|
1.98
|
| Financing Cash Flow |
|
-0.66
-100.76%
|
87.09
+1641.78%
|
5.00
-47.73%
|
9.57
|
| Cash Flow From Continuing Financing Activities |
|
-0.66
-100.76%
|
87.09
+1641.78%
|
5.00
-47.73%
|
9.57
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
78.43
|
0.00
|
—
|
| Issuance Of Debt |
|
0.00
-100.00%
|
78.43
|
0.00
|
—
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
78.43
|
0.00
|
—
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
78.43
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.76
|
0.00
|
0.00
-100.00%
|
0.03
|
| Net Other Financing Charges |
|
-1.42
-116.44%
|
8.65
+73.10%
|
5.00
|
—
|
| Changes In Cash |
|
-25.67
-133.66%
|
76.25
+976.12%
|
-8.70
-65.02%
|
-5.27
|
| Effect Of Exchange Rate Changes |
|
0.05
+1433.33%
|
0.00
|
0.00
|
—
|
| Beginning Cash Position |
|
83.60
+1037.44%
|
7.35
-54.21%
|
16.05
-24.73%
|
21.33
|
| End Cash Position |
|
57.98
-30.65%
|
83.60
+1037.44%
|
7.35
-54.21%
|
16.05
|
| Free Cash Flow |
|
-25.01
-130.68%
|
-10.84
+20.89%
|
-13.70
+7.66%
|
-14.84
|
| Issuance Of Capital Stock |
|
—
|
—
|
0.00
-100.00%
|
9.53
|
| Net Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
9.53
|
| Preferred Stock Issuance |
|
—
|
—
|
0.00
-100.00%
|
9.53
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-17 View
- 42026-04-15 View
- 8-K2026-04-13 View
- 8-K2026-04-07 View
- 42026-04-01 View
- 10-K2026-03-31 View
- 8-K2026-03-31 View
- 42026-03-20 View
- 42026-03-02 View
- 42026-03-02 View
- 8-K2026-02-26 View
- 8-K2026-02-24 View
- 8-K2026-02-24 View
- 8-K2026-02-24 View
- 42026-02-20 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
- 42026-02-09 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|